No Data
Yaokang Biological (688046.SH): a total of 0.2603% of the company's shares have been repurchased.
On May 6, Glorious Conference announced that as of April 30, 2025, the company has repurchased a total of 1,067,387 shares through the centralized auction trading system of the Shanghai Exchange, accounting for 0.2603% of the company's total share capital. The highest repurchase price was 15.13 yuan per share, the lowest price was 10.52 yuan per share, and the total amount paid was 13,914,990.75 yuan (excluding stamp duty, transaction commissions, and other trading fees).
In the first quarter, Yaokang Bio (688046.SH) reported a Net income of 29.9803 million yuan, a year-on-year increase of 1.7%.
On April 26, Gelonghui reported that Yaokang Biological (688046.SH) released its quarterly report, achieving a total operating revenue of 0.171 billion yuan in the first quarter of 2025, a year-on-year increase of 8.76%; net income attributable to shareholders of the parent company was 29.9803 million yuan, a year-on-year increase of 1.7%; and the basic EPS was 0.07 yuan.
Yakkang Biotech\'s 2025 First Quarter Report
Yakkang Biotech 2024 Annual Report
Summary of Yakkang Biotech\'s 2024 Annual Report
GemPharmatech Significantly Expands U.S. Capabilities With New San Diego Biotech Hub Facility
Investor Optimism Abounds GemPharmatech Co., Ltd. (SHSE:688046) But Growth Is Lacking
